In addition to treating patients using conventional approaches such as surgery, radiation therapy and chemotherapy, our internationally recognized bone and soft tissue cancer team also utilizes innovative surgical and medical treatment options including modular megaprostheses, custom implants, bone transplants and expandable bone implants, computerized navigated surgery, intra-operative CAT scans and clinical trials for new drugs or targeted therapeutic agents.
We were the first to develop continuous infusion ifosfamide and paclitaxel for sarcoma and among the few to offer RANKL antibody chemotherapy for giant-cell bone tumors. We also are successful in limb-salvage procedures, resulting in fewer amputations than national averages.
In addition, the University of Minnesota houses the only National Cancer Institute-funded Children’s Oncology Group phase 1 program in Minnesota. This means we offer more clinical trials than any other children’s hospital in the state. New treatments are discovered and applied here first, often becoming national standards of care. Ask your child’s physician about participating in a clinical trial.